Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 480 participants.
Also called NCT07749014
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 480 participants
- Sponsor
- Registry
-
NCT07749014
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Pakistan
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07749014. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2027-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients
- Acronym
- TEMPO-STEMI
- Condition
- ST-elevation Myocardial Infarction (STEMI)
- Condition
- Acute Myocardial Infarction (AMI)
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- empagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Rehman Medical Institute - RMI
- Collaborator
- Michigan State University
Record details
- Record id
cardio:ct-nct07749014- Content hash
6852ff9ce7cb27256364ccea2e8c0ae9cc354332edb12ca27645c0e17db2feab